New drugs in clinical development in the United States.
Over the past few years, a number of new antineoplastic agents have reached the clinical arena. These agents have demonstrated activity in a wide variety of preclinical tumor models and many have been found to have novel mechanisms of action. Some of these new agents are now in Phase I and Phase II trials demonstrating antitumor activity and unique toxicity profiles. In this article, the authors review some of the new agents in clinical development in the United States.
University of Texas Health Science Center, San Antonio.
J R
JR
Eckardt
D D
DD
Von Hoff
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D015394:Molecular Structure; D013329:Structure-Activity Relationship; D014481:United States
D000970:Antineoplastic Agents